Hims & Hers Health enters the week with the stock down another 4% — extending a bruising month that has now erased nearly 14% — while short interest edges quietly higher and the analyst community tries to find a floor.
The most important thing the positioning data says right now is that shorts are not capitulating. Short interest has ticked back up to 26.5% of the free float — roughly 58.1 million shares — a small but genuine reversal from the gradual drift lower noted in the prior week's note. The month-on-month move is still down around 4.6%, so the bigger trend remains a slow bleed of short conviction, but the week-on-week uptick of 0.6% confirms bears are rebuilding, not retreating, into the latest leg lower. The borrow market isn't flashing stress. Availability sits at 69.4%, tighter than the 75-84% range seen in late August but still well within comfortable territory, and cost to borrow has barely moved — 0.71% now versus around 0.59-0.80% across recent sessions. Shorts can add positions cheaply. The ORTEX short score has held steady just above 70 for the past two weeks, placing HIMS in the most heavily shorted decile of the broader universe — a persistent structural position rather than a new escalation. Options traders remain relaxed. The put/call ratio at 0.56 is fractionally below its 20-day average of 0.57, offering no signal of either elevated hedging demand or unusual call buying. Overall, the lending and options picture reads as a stock where bears are comfortable and bulls are not yet stepping in aggressively enough to change the dynamic.
The Street is roughly split, with a tilt toward neutrality that fits the price action. After Q2 results in August, the dominant move from analysts was to raise targets while standing pat on cautious ratings — Morgan Stanley moved its target to $28 from $21, BofA lifted to $32 from $30, and Needham (the outlier bull) raised to $42 from $35, all maintaining existing ratings. Barclays subsequently trimmed to $35 from $39 while keeping Overweight, and Truist raised its Hold target to $32 from $27 most recently on August 24. The message from the aggregate is that the quarter was better than feared, targets have moved up, but conviction upgrades haven't followed. The consensus mean target of $31.23 implies around 13% upside from Friday's close of $27.71 — meaningful in absolute terms, but the gap between "mathematically cheap" and "actually buying it" is wide when the stock has been sliding for a month. Factor scores reinforce the caution: EPS momentum ranks in the bottom decile over both 30 and 90 days, and the EPS surprise percentile of 2 suggests estimates have been running ahead of reality. The forward earnings growth picture is brighter — the 12-month forward EPS growth rank sits at 64th percentile — but quality metrics remain thin, with returns on assets still negative.
The bull and bear cases are well-understood. Bulls point to a genuinely differentiated digital health platform, strong subscriber retention, and the GLP-1 opportunity as a structural growth driver that the market is too pessimistic about. Bears focus on the intensity of competition — from both established healthcare systems moving into telehealth and better-funded startups — plus the regulatory overhang in compounded GLP-1 products, where any adverse policy development would arrive with little warning and hit margins hard. Neither case has changed materially in recent weeks; the question is whether the August earnings print, which the stock initially celebrated before handing most gains back, resolved the debate. The evidence so far says it didn't.
Insider activity is worth flagging, though context is needed. The CEO, Andrew Dudum, transferred and gifted a combined 1.4 million shares in late August. These transactions carry codes indicating non-market-facing transfers rather than open-market sales — they are compensation-related and estate/charitable in nature — and Dudum retains a substantial 9.4% economic stake per his most recent Schedule 13D/A filed August 31, down from 10.3% previously. That reduction in disclosed ownership is worth noting, even if the transaction mechanics aren't straightforwardly bearish. Separately, the CFO and CLO have both been executing small planned sales under 10b5-1 programs — modest in size and entirely consistent with routine executive liquidity. The 90-day insider net is a modest $1.7 million negative, driven almost entirely by these pre-arranged disposals. BlackRock added 2.4 million shares in its most recent filing to reach 12.3% of shares — the largest institutional position — while FMR (Fidelity) almost entirely rebuilt its position, adding 4.2 million shares to reach 1.85% of shares outstanding.
The next earnings event lands November 2. In the prior quarter, HIMS fell 3.4% the day after results and lost a further 6% over the following week — a pattern where an in-line or mildly positive print is met with relief-selling rather than follow-through buying. With the stock back near the $27-28 area that preceded the August print, the setup heading into November will be worth watching: whether shorts rebuild further before then, and whether analysts who moved targets up but not ratings finally find a reason to commit.
See the live data behind this article on ORTEX.
Open HIMS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
